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Abstract
The actin cytoskeleton has been implicated in playing an important role assembly and budding of
several RNA virus families including retroviruses and paramyxoviruses. In this report, we sought
to determine whether actin is incorporated into Ebola VLPs, and thus may play a role in assembly
and/or budding of Ebola virus. Our results indicated that actin and Ebola virus VP40 strongly co-
localized in transfected cells as determined by confocal microscopy. In addition, actin was packaged
into budding VP40 VLPs as determined by a functional budding assay and protease protection assay.
Co-expression of a membrane-anchored form of Ebola virus GP enhanced the release of both VP40
and actin in VLPs. Lastly, disruption of the actin cytoskeleton with latrunculin-A suggests that actin
may play a functional role in budding of VP40/GP VLPs. These data suggest that VP40 may interact
with cellular actin, and that actin may play a role in assembly and/or budding of Ebola VLPs.
Introduction
Ebola virus VP40 is known to bud from cells as a virus-like
particle (VLP) independent of additional virus proteins
[1-4]. The most efficient release of VP40 VLPs requires
both host proteins (e.g. tsg101 and vps4), as well as addi-
tional virus proteins (e.g. glycoprotein [GP] and nucleo-
protein [NP]) [5-7]. Cytoskeletal proteins have also been
implicated in assembly and budding of various RNA-con-
taining viruses [8-22]. Thus, we sought to determine
whether cellular actin may be important for Ebola virus
VP40 VLP budding.
Results
First, we sought to detect actin in budding VP40 VLPs.
Human 293T cells were mock-transfected, or transfected
with VP40 alone, VP40 + GP, VP40 + a mucin domain
deletion mutant (GP∆M), or VP40 + secreted GP (sGP)
(Fig. 1A). VP40 synthesis in all cell extracts is shown as an
expression control (Fig. 1A, cells). As expected, VP40
alone was readily detected in budding VLPs; however,
actin was weakly detectable in VLPs containing VP40
alone (Fig. 1A, VLPs, lane 2). Co-expression of either full-
length wild type GP (lane 3), or GP∆M (lane 4) resulted
in enhanced release of VP40. Similarly, release of cellular
actin was also enhanced in VP40 VLPs containing full-
length GP (lane 3), or GP∆M (lanes 4). In contrast, co-
expression of sGP (lane 5) did not enhance release of
either VP40 or actin (compare lanes 2 and 5). Both VP40
and actin were enhanced 5–6 fold (determined by phos-
phoimager analysis) in VLPs when GP or GP∆M were co-
expressed along with VP40 compared to that when VP40
was expressed alone (data not shown). These results sug-
gest that actin can be packaged in budding VP40 VLPs,
and that co-expression of a membrane-anchored form of
GP equally enhances release of both VP40 and actin. In
addition, GP-mediated enhancement of VP40 VLP bud-
ding and actin packaging into VLPs is independent of the
mucin-like domain of GP.
Published: 20 December 2005
Virology Journal 2005, 2:92 doi:10.1186/1743-422X-2-92
Received: 05 August 2005
Accepted: 20 December 2005
This article is available from: http://www.virologyj.com/content/2/1/92
© 2005 Han and Harty; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Virology Journal 2005, 2:92 http://www.virologyj.com/content/2/1/92
Page 2 of 5
(page number not for citation purposes)
To confirm that actin was indeed incorporated into VP40/
GP VLPs and does not represent a cellular contaminant,
protease protection (Fig. 1B) and flotation gradient anal-
yses (data not shown) were performed. Radiolabeled
VP40 VLPs were divided into equal aliquots and treated as
indicated in Fig. 1B. Following treatment, β-actin and
VP40 were detected by immunoprecipitation and ana-
lyzed by SDS-PAGE (Fig. 1B). As reported previously
[2,3,6], VP40 was only degraded completely by trypsin in
the presence of TX-100 (Fig. 1B lane 3). Similarly, actin
was also only degraded completely by trypsin in the pres-
ence of TX-100 (lane 3). Treatment with trypsin alone was
not sufficient to degrade either VP40 or actin (lane 2).
These findings indicate that cellular actin is indeed pack-
aged within Ebola virus VLPs. It should be noted that flo-
tation gradients of purified VLPs were also utilized to
demonstrate that actin, VP40, and GP co-purified together
in the upper fractions (fractions 2 and 3) of the VLP gradi-
ent (data not shown). These findings are consistent with
those presented above that actin is incorporated into bud-
ding VLPs.
We next sought to use immunofluorescence and confocal
microscopy to determine whether VP40 colocalized with
cellular actin in COS-1 cells (Fig. 1C). VP40 (green) is
known to localize to the cell periphery and can be visual-
ized in membrane fragments or blebs (VLPs) being
released from the cell (Fig. 1C). Cellular actin (red) was
Packaging of actin into VLPs Figure 1
Packaging of actin into VLPs. A) Human 293T cells were mock-transfected (lane 1), or transfected with VP40 alone (lane 2), 
VP40 + GP (lane 3), VP40 + GP∆M (lane 4), or VP40 + sGP (lane 5). Radiolabeled VP40 was detected in cell extracts (cells) and 
in VLPs. Actin was detected in VLPs by immunoprecipitation using an anti-actin polyclonal Ab. B) VP40 VLP samples were 
untreated (lane 1), treated with trypsin alone (lane 2), or treated with trypsin + TX-100 (lane 3). VP40 and actin were detected 
by immunoprecipitation. C) Indirect immunofluorescence of VP40 (green) and actin (red) with the merged image shown in yel-
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detected by the use of a polyclonal anti-actin antibody
(Santa Cruz Biotechnology, Inc.). Upon merging of the
two images, VP40 and actin were found to colocalize (yel-
low) in many of the membrane fragments that likely rep-
resent the formation of VLPs (Fig. 1C). These results
correlate with those described above to suggest that VP40
may interact with actin, and that actin may be incorpo-
rated into budding VLPs in a specific manner.
Latrunculin-A, which disrupts actin filaments by binding
actin monomers to prevent them from polymerizing, was
used to disrupt the actin cytoskeleton. Concentrations of
latrunculin-A utilized in these experiments were shown to
disrupt actin filaments by immunofluorescence staining
(data not shown). Human 293-T cells were transfected
with VP40 alone, or with VP40 + full-length GP (Fig. 2).
At 24 hours post-transfection, cells were pretreated with or
without the indicated concentrations of latrunculin-A for
20 min. and were then radiolabeled with [35S]Met-Cys in
the presence or absence of latrunculin-A for 5 hours. VLPs
and cell extracts were prepared as described above. VP40
(panel A) and actin (panel B) in VLPs were detected by
immunoprecipitation and analyzed by phosphor-imager
analyses. Interestingly, VP40 VLP release was slightly stim-
ulated in the presence of 1.0 and 2.5 µM latrunculin-A
(Fig. 2A, lanes 3 and 4), compared to that in the absence
of drug (lane 2). A similar result was observed in the pres-
ence of identical concentrations of cytochalasin D (data
not shown). In contrast, release of VP40/GP VLPs was
slightly reduced in the presence of Lat-A (Fig. 2A, lanes 6
and 7), compared to that in the absence of drug (lane 5).
The effect of Lat-A on packaging of actin into VLPs paral-
leled that of VP40 (Fig. 2B). For example, in the presence
of 1.0 and 2.5 µM lat-A, slightly more actin was packaged
into VP40 VLPs (Fig. 2B, lanes 3 and 4) than that in the
absence of drug (lane 2). In contrast, reduced amounts of
actin were packaged into VP40/GP VLPs in the presence of
lat-A (Fig. 2B, lanes 6 and 7) than in the absence of drug
(lane 5). These results indicate that lat-A partially inhibits
both VP40 and actin release in VLPs only when VP40 and
GP are co-expressed in cells. However, lat-A treatment
slightly enhanced release of VP40 budding alone. Treat-
ment with actin depolymerizing drugs has been reported
to both increase and decrease budding of other RNA
viruses [9,10,18,23,24].
Discussion
The mechanism by which GP enhances budding of VP40
VLPs remains unclear [6]. Preliminary data from our lab
suggests that GP does not enhance budding of VP40 via a
direct protein-protein interaction (data not shown). An
alternative possibility is that GP modifies the cell in a glo-
bal manner that positively influences VP40 release.
Indeed, GP is known to be cytotoxic and induces cell
rounding and detachment [25-27]. Thus, GP expression
likely induces significant changes to the cellular cytoskel-
Affect of Latrunculin-A on VLP budding Figure 2
Affect of Latrunculin-A on VLP budding. VLPs were isolated from mock-transfected cells or cells transfected with VP40 alone 
or VP40 + GP in theabsence, or presence of the indicated concentration of lat-A. VP40 (panel A) or actin (panel B) was 
detected by immunoprecipitation and quantitated by phosphoimager analysis of at least two independent experiments.Virology Journal 2005, 2:92 http://www.virologyj.com/content/2/1/92
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eton during infection. Lat-A may be inhibiting the mech-
anism by which GP enhances budding of VP40 (Fig. 2). It
remains to be determined whether actin directly interacts
with VP40, or whether actin may directly interact with GP.
The actin cytoskeleton has been implicated in assembly
and budding of Newcastle disease virus, HIV-1, Black
Creek Canal Virus, fowlpox virus, West Nile virus, equine
infectious anemia virus, and respiratory syncytial virus
RSV [9,10,14,18,20,23,24]. Cellular actin has been
detected in virion or virus-like particles of murine mam-
mary tumor virus (MuMTV), Moloney murine leukemia
virus (MoMuLV), HIV-1, and Sendai virus
[11,13,15,16,28]. Ebola virus VP40 has recently been
shown to associate with microtubules and enhance tubu-
lin polymerization [19]. Yonezawa et al. found that agents
that inhibited microfilaments also inhibited entry and
fusion of Ebola virus GP pseudotypes [29]. These authors
suggest that microtubules and microfilaments may play a
role in trafficking Ebola virions from the cell surface to
acidified vesicles for fusion.
Conclusion
Our data indicate that actin is indeed packaged into Ebola
virus VLPs. Co-expression of a membrane-anchored form
of GP enhances release of actin and VP40 by equivalent
levels in VLPs. The mucin-like domain of GP was not nec-
essary for enhancement of VP40 or actin release in VLPs.
VP40 was found to co-localize with actin suggesting that
VP40 may interact with actin and perhaps may utilize the
actin network for assembly and budding VLPs from the
plasma-membrane. Lat-A treatment resulted in a slight
increase in budding of VP40 VLPs; however, the same con-
centrations of lat-A resulted in a slight decrease in bud-
ding of VP40/GP VLPs. Experiments are now underway to
understand further the mechanism of action of lat-A and
other actin depolymerizing drugs on Ebola VLP budding.
In addition, we will attempt to determine whether actin
binding proteins may be involved in VLP budding. Lastly,
experiments are underway to determine whether actin
plays a role in assembly and budding of live Ebola virus.
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